<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="2-part\PMC6789600\results\search\tropicalVirus\results.xml">
  <result pre="Medicine and Infectious Disease2414-6366MDPI pmcid: 6789600 doi: 10.3390/tropicalmed4030104tropicalmed-04-00104 : Review" exact="Zika" post="Vaccine Development—Current Progress and Challenges for the Future https://orcid.org/0000-0003-0305-5608MaslowJoel"/>
  <result pre="an employee of GeneOne Life Science, a developer of a" exact="Zika" post="vaccine. epub: 2019-7-7collection: 2019-943104received: 2019-6-11accepted: 2019-7-11(C) , 2019Licensee MDPI,"/>
  <result pre="of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract" exact="Zika" post="virus is an emergent pathogen that gained significant importance"/>
  <result pre="infection causing microcephaly, blindness, and other congenital neurologic complications. Numerous" exact="Zika" post="virus vaccines were developed, with nine different vaccines representing"/>
  <result pre="II. Here we review the current landscape and challenges confronting" exact="Zika" post="virus vaccine development. Zika virus flavivirus emerging infectious disease"/>
  <result pre="the current landscape and challenges confronting Zika virus vaccine development." exact="Zika" post="virus flavivirus emerging infectious disease vaccine sample size 1."/>
  <result pre="flavivirus emerging infectious disease vaccine sample size 1. Introduction The" exact="Zika" post="virus, discovered in Uganda in 1947 [1], was shown"/>
  <result pre="and on French Polynesia in 2014 [4]. Starting in mid-2015," exact="Zika" post="virus infection achieved epidemic status, spreading rapidly through South"/>
  <result pre="and the Caribbean Islands [5]. It was soon recognized that" exact="Zika" post="virus infection occurring during pregnancy caused microcephaly and other"/>
  <result pre="the primary reason for the World Health Organization (WHO) labelling" exact="Zika" post="as an international threat in early 2016. Beginning in"/>
  <result pre="by the time the first vaccines entered clinical trials, the" exact="Zika" post="epidemic had started to wane creating significant challenges to"/>
  <result pre="paper, we provide a brief update of current progress in" exact="Zika" post="virus vaccine development and explore the challenges to vaccine"/>
  <result pre="explore the challenges to vaccine assessment and eventual licensure. 2." exact="Zika" post="Vaccine Target Population Zika virus infection presents with a"/>
  <result pre="vaccine assessment and eventual licensure. 2. Zika Vaccine Target Population" exact="Zika" post="virus infection presents with a symptom complex consisting of"/>
  <result pre="that only 19% of survey participants reported symptoms consistent with" exact="Zika" post="virus infection [3], a figure that has been cited"/>
  <result pre="[3], a figure that has been cited to suggest that" exact="Zika" post="virus infection is asymptomatic in as many as 80%"/>
  <result pre="those with evidence of prior infection had symptoms consistent with" exact="Zika" post="virus infection [11]. A more recent meta-analysis of 23"/>
  <result pre="studies [12]. In adults, the most common reported complication of" exact="Zika" post="virus infection is a Guillain–Barré-like illness that had a"/>
  <result pre="30% children born to mothers infected during pregnancy [16,17,18,19,20,21]. Additionally," exact="Zika" post="can directly invade the placenta and has been associated"/>
  <result pre="placenta and has been associated with prolonged maternal viremia [22,23,24]." exact="Zika" post="virus can also be transmitted through sexual contact, first"/>
  <result pre="is unknown and could not be differentiated from mosquito-borne transmission." exact="Zika" post="virus carriage in the male urogenital tract is common"/>
  <result pre="may persist in some to 9 months [27]. In mice," exact="Zika" post="virus infection causes testicular atrophy and significantly decreases spermatic"/>
  <result pre="function and fertility rates [28,29,30]. In one study of a" exact="Zika" post="virus DNA vaccine, the adverse effects in the male"/>
  <result pre="system were prevented by vaccination [30]. The question of whether" exact="Zika" post="virus can adversely affect human reproductive potential and, if"/>
  <result pre="effects would be age-related is unknown. Females may also excrete" exact="Zika" post="virus RNA for extended times. A prospective study of"/>
  <result pre="extended times. A prospective study of five women showed that" exact="Zika" post="RNA was detected in vaginal fluid for as long"/>
  <result pre="in three of the five [31]. Murine studies showed that" exact="Zika" post="virus caused infection of the ovaries of non-immunosuppressed C57Bl/6"/>
  <result pre="rapidly cleared virus from the genital tract [33]. Thus, while" exact="Zika" post="virus infection is mildly symptomatic and self-limited for the"/>
  <result pre="been put on hold due to the decreasing incidence of" exact="Zika" post="infection rates, as discussed in the next section. 3."/>
  <result pre="discussed in the next section. 3. Changing Epidemiology of the" exact="Zika" post="Virus Outbreak In late 2015 and through mid-2016, global"/>
  <result pre="was predictive of the subsequent epidemiology in the Americas. The" exact="Zika" post="virus outbreaks in Yap Island and French Polynesia were"/>
  <result pre="rapid resolution over a span of 3–4 months [3,9]. The" exact="Zika" post="epidemic in the Americas was characterized by a longer"/>
  <result pre="South and Central America (https://www.paho.org/). The almost complete disappearance of" exact="Zika" post="has created significant barriers to ongoing vaccine studies as"/>
  <result pre="reasonable sample sizes [6]. The WHO removed the designation of" exact="Zika" post="a virus of global concern in 2018 as case"/>
  <result pre="representatives from industry, and regulators to discuss the approach to" exact="Zika" post="virus vaccine development in an era of waning incidence"/>
  <result pre="vaccine development in an era of waning incidence [7]. Although" exact="Zika" post="virus remains endemic in Asia, Africa, and Central and"/>
  <result pre="rapid response to new reports suggesting increased disease activity. 4." exact="Zika" post="Vaccine Candidates in Development Vaccine development against the Zika"/>
  <result pre="4. Zika Vaccine Candidates in Development Vaccine development against the" exact="Zika" post="virus began in earnest in late 2015 following the"/>
  <result pre="of a 1953 study to define the ultrastructural characteristics of" exact="Zika" post="virus, that found intramuscular vaccination of mice with infectious"/>
  <result pre="Poland et al. provide a comprehensive listing of almost 40" exact="Zika" post="virus vaccines in development as of 2017 [37]. Diamond"/>
  <result pre="[37]. Diamond et al. discuss potential immunoreactive epitopes on the" exact="Zika" post="envelope and provide further information on those vaccines that"/>
  <result pre="II (Table 1). GLS-5700, a DNA vaccine encoding for the" exact="Zika" post="virus prME genes designed as a consensus based on"/>
  <result pre="virus prME genes designed as a consensus based on available" exact="Zika" post="virus sequences through December 2015 [43], was the first"/>
  <result pre="shown to develop B and T-cell immune responses against the" exact="Zika" post="virus envelope and protected against development of neurologic disease"/>
  <result pre="that included the JEV prM signal sequence followed by the" exact="Zika" post="envelope (E) gene (VRC5283) or a similar construct with"/>
  <result pre="and subcutaneously vaccinated mice were only partially protected against the" exact="Zika" post="Brazil strain [46]. A subsequent study in non-human primates"/>
  <result pre="following challenge with either Brazilian or Puerto Rican strains of" exact="Zika" post="virus [47]. ZPIV safety and immunogenicity was tested in"/>
  <result pre="and immunogenicity was tested in three clinical trials to assess" exact="Zika" post="vaccine responses relative to dose level, vaccination schedule, or"/>
  <result pre="day 57. Passive transfer of purified IgG derived from 10" exact="Zika" post="immunized participants to groups of 5 Balb/C mice per"/>
  <result pre="that incorporates the prM-E genes of a Micronesian strain of" exact="Zika" post="virus was created incorporating with or without four-point mutations"/>
  <result pre="strain PRVABC59 selected as without passage-related mutations, protected against lethal" exact="Zika" post="virus challenge in AG129 mice when administered with alum"/>
  <result pre="administered with alum adjuvant [49]. A measles-vectored vaccine encoding the" exact="Zika" post="virus prME was shown to lessen viremia in pregnant"/>
  <result pre="knockout mice (AG129 or IFNAR -/-) develop lethal infection following" exact="Zika" post="virus infection and have been used as a more"/>
  <result pre="human challenge trials raises unique medical and ethical considerations. For" exact="Zika" post="virus trials, one must balance the relative benign and"/>
  <result pre="transmission risks. As reviewed above, published studies provide estimates that" exact="Zika" post="virus infection is relatively asymptomatic and self-limited for the"/>
  <result pre="above, a Guillain–Barre-like syndrome occurs in approximately 1 of 5000" exact="Zika" post="virus infections [13], whereas other neurologic complications such as"/>
  <result pre="a sexual partner and the potential for infection during pregnancy." exact="Zika" post="virus commonly persists in the male urogenital tract for"/>
  <result pre="[27]. Some have considered limiting studies to non-pregnant females as" exact="Zika" post="virus colonization of the female genital tract may be"/>
  <result pre="female genital tract may be temporally limited. The fact that" exact="Zika" post="virus is known to cause testicular atrophy in mice"/>
  <result pre="challenge strain is as yet undetermined. 7. Summary In summary," exact="Zika" post="vaccine development continues with multiple candidate vaccines in clinical"/>
  <result pre="a developer of DNA-based vaccines including a vaccine against the" exact="Zika" post="virus. Abbreviations WRAIR Walter Reed Army Institute of Research"/>
  <result pre="4.collab: European Centre for Disease Prevention and ControlRapid risk assessment:" exact="Zika" post="virus infection outbreak, French PolynesiaProceedings of the ECDCStockholm, Sweden14"/>
  <result pre="Americas—Yet another arbovirus threatN. Engl. J. Med.201637460160410.1056/NEJMp160029726761185 6.CohenJ.Steep drop in" exact="Zika" post="cases undermines vaccine trialScience20183611055105610.1126/science.361.6407.105530213891 7.VanniceK.S.CassettiM.C.EisingerR.W.HombachJ.KnezevicI.MarstonH.D.Wilder-SmithaA.CavaleridM.KrauseeP.R.Demonstrating vaccine effectiveness during a"/>
  <result pre="WHO/NIH meeting report on approaches to development and licensure of" exact="Zika" post="vaccine candidatesVaccine20193786386810.1016/j.vaccine.2018.12.04030639461 8.Cao-LormeauV.M.RocheC.TeissierA.RobinE.BerryA.-L.MalletH.P.SallA.A.MussoD.Zika virus, French Polynesia, South Pacific, 2013Emerg."/>
  <result pre="South Pacific, 2013Emerg. Infect. Dis.2014201086108710.3201/eid2011.141380 9.MalletH.P.VialA.L.MussoD.Bilan de l’épidémie à virus" exact="Zika" post="survenue en Polynésie française entre octobre 2013 et mars"/>
  <result pre="aux connaissances acquises après l’évènementBulletin Épidémiologique Hebdomadaire201620–21367373 10.MussoD.NhanT.RobinE.RocheC.BierlaireD.ZisouK.Shan YanA.Cao-LormeauV.M.BroultJ.Potential for" exact="Zika" post="virus transmission through blood transfusion demonstrated during an outbreak"/>
  <result pre="virus seroprevalence, French Polynesia, 2014–2015Emerg. Infect. Dis.20172366967210.3201/eid2304.16154928084987 12.HabyM.M.PinartM.EliasV.ReveizL.Prevalence of asymptomatic" exact="Zika" post="virus infection: A systematic reviewBull. World Health Org.201896402D413D10.2471/BLT.17.20154129904223 13.Cao-LormeauV.M.BlakeA.MonsS.LastereS.RocheC.VanhomwegenJ.DubT.BaudouinL.TeissieraA.LarreP.et"/>
  <result pre="reviewBull. World Health Org.201896402D413D10.2471/BLT.17.20154129904223 13.Cao-LormeauV.M.BlakeA.MonsS.LastereS.RocheC.VanhomwegenJ.DubT.BaudouinL.TeissieraA.LarreP.et al.Guillain-Barre Syndrome outbreak associated with" exact="Zika" post="virus infection in French Polynesia: A case-control studyLancet20163871531153910.1016/S0140-6736(16)00562-626948433 14.BautistaL.E.Zika"/>
  <result pre="dysfunction in fetuses and newborns following the 2013 to 2014" exact="Zika" post="virus epidemic in French PolynesiaEuro Surv.201621223010.2807/1560-7917.ES.2016.21.13.3018127063794 17.BrasilP.PereiraJ.P.MoreiraM.E.NogueiraR.M.R.DamascenoL.WakimotoM.RabelloR.S.ValderramosS.G.HalaiU.-A.SallesT.S.et al.Zika virus"/>
  <result pre="18.collab: European Centre for Disease Prevention and ControlRapid risk assessment:" exact="Zika" post="virus epidemic in the Americas: Potential association with microcephaly"/>
  <result pre="fetuses and infants of US women with evidence of possible" exact="Zika" post="virus infection during pregnancyJAMA201717596810.1001/jama.2016.19006 20.LealM.C.MunizL.F.FerreiraT.S.A.SantosC.M.AlmeidaL.C.Van Der LindenV.RamosR.C.F.RodriguesL.C.NetoS.S.C.Hearing loss in"/>
  <result pre="LindenV.RamosR.C.F.RodriguesL.C.NetoS.S.C.Hearing loss in infants with microcephaly and evidence of congenital" exact="Zika" post="virus infection—Brazil, November 2015–May 2016MMWR20166591791910.15585/mmwr.mm6534e327585248 21.VenturaC.V.MaiaM.TravassosS.B.MartinsT.T.PatriotaF.NunesM.E.AgraC.TorresV.L.van der LindenV.RamosR.C.et al.Risk"/>
  <result pre="associated with the ophthalmoscopic findings identifed in infants with presumed" exact="Zika" post="virus congenital infectionJAMA Ophthalmol.201613491291810.1001/jamaophthalmol.2016.178427228275 22.DriggersR.W.HoC.Y.KorhonenE.M.KuivanenS.JääskeläinenA.J.SmuraT.RosenbergA.HillA.DeBiasiR.L.VezinaG.et al.Zika virus infection with"/>
  <result pre="brain abnormalitiesN. Engl. J. Med.201610.1056/NEJMoa1601824 23.Meaney-DelmanD.OduyeboT.PolenK.N.D.WhiteJ.L.BinghamA.M.SlavinskiS.A.Heberlein-LarsonL.St. GeorgeK.RakemanJ.L.HillsS.et al.Prolonged detection of" exact="Zika" post="virus RNA in pregnant womenObstet. Gynecol.201612872473010.1097/AOG.000000000000162527479770 24.Oliveira MeloA.S.MalingerG.XimenesR.SzejnfeldP.O.Alves SampaioS.Bispo"/>
  <result pre="iceberg?Ultrasound Obstet. Gynecol.2016476710.1002/uog.1583126731034 25.FoyB.D.KobylinskiK.C.Chilson FoyJ.L.BlitvichB.J.Travassos da RosaA.HaddowA.D.LanciottiR.S.RobertB.TeshR.B.Probable non-vector-borne transmission of" exact="Zika" post="virus, Colorado, USAEmerg. Infect. Dis.20111788088210.3201/eid1705.10193921529401 26.DuggalN.K.RitterJ.M.PestoriusS.E.ZakiS.R.DavisB.S.ChangG.J.BowenR.A.BraultA.C.Frequent Zika virus sexual"/>
  <result pre="non-vector-borne transmission of Zika virus, Colorado, USAEmerg. Infect. Dis.20111788088210.3201/eid1705.10193921529401 26.DuggalN.K.RitterJ.M.PestoriusS.E.ZakiS.R.DavisB.S.ChangG.J.BowenR.A.BraultA.C.Frequent" exact="Zika" post="virus sexual transmission and prolonged viral RNA shedding in"/>
  <result pre="in miceNature201654043844210.1038/nature2055627798603 30.GriffinB.D.MuthumaniK.WarnerB.M.MajerA.HaaganM.AudetJ.SteinD.R.RanadheeraC.RacineT.De La VegaM.-A.et al.DNA vaccination protects mice against" exact="Zika" post="virus-induced damage to the testesNat. Commun.201781574310.1038/ncomms1574328589934 31.ReyesY.BowmanN.M.Becker-DrepsS.CentenoE.CollinsM.H.LiouG.A.BucardoF.Prolonged shedding of"/>
  <result pre="Zika virus-induced damage to the testesNat. Commun.201781574310.1038/ncomms1574328589934 31.ReyesY.BowmanN.M.Becker-DrepsS.CentenoE.CollinsM.H.LiouG.A.BucardoF.Prolonged shedding of" exact="Zika" post="virus RNA in vaginal secretions, NicaraguaEmerg. Infect. Dis.20192580881010.3201/eid2504.18097730882329 32.CaineE.A.ScheafferS.M.BroughtonD.E.SalazarV.GoveroJ.PoddarS.OsulaA.HalabiJ.Skaznik-WikielM.E.DiamondM.S.et"/>
  <result pre="DC, USA2017 36.ReaganR.L.BrueknerA.L.Comparison by electron microscopy of the Ntaya and" exact="Zika" post="virusesTex. Rep. Biol. Med.19531134735113077401 37.PolandG.A.KennedyR.B.OvsyannikovaI.G.PalaciosR.HoP.L.KalilJ.Development of vaccines against Zika"/>
  <result pre="and Zika virusesTex. Rep. Biol. Med.19531134735113077401 37.PolandG.A.KennedyR.B.OvsyannikovaI.G.PalaciosR.HoP.L.KalilJ.Development of vaccines against" exact="Zika" post="virusLancet Infect. Dis.201818e211e21910.1016/S1473-3099(18)30063-X29396004 38.DiamondM.S.LedgerwoodJ.E.PiersonT.C.Zika virus vaccine development: Progress in"/>
  <result pre="39.MaslowJ.N.Vaccines for emerging infectious diseases: Lessonso from MERS coronavirus and" exact="Zika" post="virusHum. Vaccin. Immunother.2017122918293010.1080/21645515.2017.135832528846484 40.DurbinA.Wilder-SmithA.An update on Zika vaccine developmentsExpert"/>
  <result pre="MERS coronavirus and Zika virusHum. Vaccin. Immunother.2017122918293010.1080/21645515.2017.135832528846484 40.DurbinA.Wilder-SmithA.An update on" exact="Zika" post="vaccine developmentsExpert Rev. Vaccin.20171678178710.1080/14760584.2017.1345309 41.GaudinskiM.R.HouserK.V.MorabitoK.M.HuZ.YamshchikovG.RothwellR.S.BerkowitzN.MendozaF.SaundersJ.G.NovikL.et al.Safety, tolerability, and immunogenicity"/>
  <result pre="developmentsExpert Rev. Vaccin.20171678178710.1080/14760584.2017.1345309 41.GaudinskiM.R.HouserK.V.MorabitoK.M.HuZ.YamshchikovG.RothwellR.S.BerkowitzN.MendozaF.SaundersJ.G.NovikL.et al.Safety, tolerability, and immunogenicity of two" exact="Zika" post="virus DNA vaccine candidates in healthy adults: Randomised, open-label,"/>
  <result pre="vaccine—Preliminary ReportN. Engl. J. Med.2017201710.1056/NEJMoa1708120 43.MuthumaniK.GriffinB.D.AgarwalS.KudchodkarS.ReuschelE.L.ChoiH.KraynyakK.A.DuperretE.K.KeatonA.A.ChungC.et al.In vivo protection against" exact="ZIKV" post="infection and pathogenesis through passive antibody transfer and active"/>
  <result pre="vaccineNPJ Vaccin.201611602110.1038/npjvaccines.2016.21 44.DowdK.A.KoS.-Y.MorabitoK.M.YangE.S.PelcR.S.DeMasoC.R.CastilhoL.R.AbbinkP.BoydM.NityanandamR.et al.Rapid development of a DNA vaccine for" exact="Zika" post="virusScience201635423724010.1126/science.aai913727708058 45.ModjarradK.LinL.GeorgeS.L.StephensonK.E.EckelsK.H.De La BarreraR.A.JarmanR.G.SondergaardE.TennantJ.AnselJ.L.et al.Preliminary aggregate safety and immunogenicity"/>
  <result pre="and immunogenicity results from three trials of a purified inactivated" exact="Zika" post="virus vaccine candidate: Phase 1, randomised, double-blind, placebo-controlled clinical"/>
  <result pre="randomised, double-blind, placebo-controlled clinical trialsLancet20183911012010.1016/S0140-6736(17)33106-9 46.LaroccaR.A.AbbinkP.PeronJ.P.S.de AZanottoP.M.IampietroM.J.Badamchi-ZadehA.BoydM.Ng’ang’aD.KirilovaM.NityanandamR.et al.Vaccine protection against" exact="Zika" post="virus from BrazilNature201653647447810.1038/nature1895227355570 47.AbbinkP.LaroccaR.A.De La BarreraR.A.BricaultC.A.MoseleyE.T.BoydM.KirilovaM.LiZ.Ng’ang’aD.NanayakkaraO.et al.Protective efficacy of"/>
  <result pre="47.AbbinkP.LaroccaR.A.De La BarreraR.A.BricaultC.A.MoseleyE.T.BoydM.KirilovaM.LiZ.Ng’ang’aD.NanayakkaraO.et al.Protective efficacy of multiple vaccine platforms against" exact="Zika" post="virus challenge in rhesus monkeysScience20163531129113310.1126/science.aah615727492477 48.RichnerJ.M.HimansuS.BultlerS.L.SalazarV.FoxJ.M.JulanderJ.G.TangW.W.ShrestaS.PiersonT.C.CiaramellaG.et al.Modified mRNA vaccines"/>
  <result pre="challenge in rhesus monkeysScience20163531129113310.1126/science.aah615727492477 48.RichnerJ.M.HimansuS.BultlerS.L.SalazarV.FoxJ.M.JulanderJ.G.TangW.W.ShrestaS.PiersonT.C.CiaramellaG.et al.Modified mRNA vaccines protect against" exact="Zika" post="virus infectionCell20171681114112510.1016/j.cell.2017.02.01728222903 49.BaldwinW.R.LivengoodJ.A.GieblerH.A.StovallJ.L.BoroughsK.L.SonnbergS.BohningK.J.DietrichE.A.OngY.T.DanhH.K.et al.Purified inactivated Zika vaccine candidates afford"/>
  <result pre="mRNA vaccines protect against Zika virus infectionCell20171681114112510.1016/j.cell.2017.02.01728222903 49.BaldwinW.R.LivengoodJ.A.GieblerH.A.StovallJ.L.BoroughsK.L.SonnbergS.BohningK.J.DietrichE.A.OngY.T.DanhH.K.et al.Purified inactivated" exact="Zika" post="vaccine candidates afford protection against lethal challenge in miceSci."/>
  <result pre="miceSci. Rep.201881650910.1038/s41598-018-34735-730405178 50.NürnbergerC.BodmerB.S.FiedlerA.H.GabrielG.MühlebachM.D.A measles virus-based vaccine candidate mediates protection against" exact="Zika" post="virus in an allogeneic mouse pregnancy modelJ. Virol.20199310.1128/JVI.01485-18 51.MorrisonT.E.DiamondM.S.Animal"/>
  <result pre="in an allogeneic mouse pregnancy modelJ. Virol.20199310.1128/JVI.01485-18 51.MorrisonT.E.DiamondM.S.Animal models of" exact="Zika" post="virus infection, pathogenesis, and immunityJ. Virol.20179110.1128/JVI.00009-17 52.MinerJ.J.CaoB.GoveroJ.SmithA.M.FernandezE.CabreraO.H.GarberC.NollM.KleinR.S.NoguchiK.K.et al.Zika virus"/>
  <result pre="and fetal demiseCell201616511110.1016/j.cell.2016.05.008 53.BarcellosC.XavierD.R.PavãoA.BoccoliniC.S.PinaM.F.PedrosoF.P.M.RomeroD.RomãoR.A.Increased hospitalizations for neuropathies as indicators of" exact="Zika" post="virus infection, according to Health Information System data, BrazilEmerg."/>
  <result pre="Azevedo MarquesE.T.Jr.PenaL.J.Guillain-Barré syndrome, acute disseminated encephalomyelitis and encephalitis associated with" exact="Zika" post="virus infection in Brazil: Detection of viral RNA and"/>
  <result pre="during late infectionAm. J. Trop. Med. Hyg.2017971405140910.4269/ajtmh.17-010629140242 55.ShahS.K.KimmelmanJ.LyerlyA.D.LynchH.F.McCutchanF.MillerF.G.PalaciosR.Pardo-VillamizarC.ZorrillaC.Ethical Considerations for" exact="Zika" post="Virus Human Challenge TrialsNational Institutes of Health, National Institute"/>
  <result pre="for controlled human infectionJ. Infect. Dis.2017216Suppl. 10S971S97510.1093/infdis/jix49129267920 tropicalmed-04-00104-t001_Table 1Table 1" exact="Zika" post="vaccines in clinical development. Vaccine Type/Vaccine Name Developer Development"/>
 </snippets>
</snippetsTree>
